| Literature DB >> 32304108 |
Youngchang Kim1,2, Robert Jedrzejczak1,2, Natalia I Maltseva1,2, Mateusz Wilamowski1,3, Michael Endres2, Adam Godzik4, Karolina Michalska1,2, Andrzej Joachimiak1,2,3.
Abstract
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is rapidly spreading around the world. There is no existing vaccine or proven drug to prevent infections and stop virus proliferation. Although this virus is similar to human and animal SARS-CoVs and Middle East Respiratory Syndrome coronavirus (MERS-CoVs), the detailed information about SARS-CoV-2 proteins structures and functions is urgently needed to rapidly develop effective vaccines, antibodies, and antivirals. We applied high-throughput protein production and structure determination pipeline at the Center for Structural Genomics of Infectious Diseases to produce SARS-CoV-2 proteins and structures. Here we report two high-resolution crystal structures of endoribonuclease Nsp15/NendoU. We compare these structures with previously reported homologs from SARS and MERS coronaviruses.Entities:
Keywords: COVID-19; EndoU family; NendoU; Nsp15; SARS-CoV-2; crystal structure; endoribonuclease
Mesh:
Substances:
Year: 2020 PMID: 32304108 PMCID: PMC7264519 DOI: 10.1002/pro.3873
Source DB: PubMed Journal: Protein Sci ISSN: 0961-8368 Impact factor: 6.993
Data processing and refinement statistics
| Data processing | ||
|---|---|---|
| Structure | Nsp15/apo | Nsp15/cit |
| Wavelength (Å) | 0.9792 | 0.9792 |
| Resolution range (Å) | 2.20–45.10 (2.20–2.24) | 1.90–44.90 (1.90–1.93) |
| Space group | P63 | P63 |
| Unit cell (Å) |
|
|
| Unique reflections, merged | 71,416 (3,176) | 111,894 (5,660) |
| Multiplicity | 5.1 (2.6) | 5.3 (5.1) |
| Completeness (%) | 98.5 (88.3) | 99.3 (99.7) |
| Mean I/sigma(I) | 10.1 (1.08) | 13.1 (1.43) |
| Wilson B‐factor (Å2) | 36.67 | 31.50 |
| R‐merge | 0.174 (0.924) | 0.122 (1.525) |
| CC1/2 | 0.967 (0.358) | 0.982 (0.586) |
Abbreviation: PDB, protein data bank; TLS, translation/libration/screw.
Values in parentheses correspond to the highest resolution shell.
Rmerge = ∑h∑j|Ihj–
As defined by Karplus and Diederichs.
R = ∑h|Fo|–|Fc|/∑h|Fo| for all reflections, where Fo and Fc are observed and calculated structure factors, respectively. Rfree is calculated analogously for the test reflections, randomly selected and excluded from the refinement.
As defined by Molprobity.
FIGURE 1The structure of SARS‐CoV‐2 monomer
FIGURE 2Superposition of Nsp15 monomers: SARS‐CoV‐2 (teal, Chain A; blue, Chain B), SARS‐CoV (pink), and MERS‐CoV (grey)
FIGURE 3Sequence alignment of SARS‐CoV‐2 Nsp15 coronaviral homologs with structures available in the PDB: SARS‐CoV‐2 (6VWW), SARS‐CoV (2H85), MERS‐CoV (5YVD), and H‐CoV‐229E (4RS4) MHV (2GTH). The secondary structure elements labeled for SARS‐CoV‐2 Nsp15
FIGURE 4Structure of SARS‐CoV‐2 hexamer in surface representation with each subunit shown in different color. The active site residues are colored red
FIGURE 5Active site of SARS‐CoV‐2 Nsp15 NendoU. (a) Superposition of the SARS‐CoV‐2 Nsp15 active site with its homologs: SARS‐CoV‐2 (teal, Chain A), SARS‐CoV (pink), and MERS‐CoV (grey) and (b) Binding of citrate to the Nsp15 active site
FIGURE 6Nsp15 endoribonuclease assay and differential scanning fluorimetry. (a) Time‐dependent cleavage of the oligonucleotide 5′‐6‐FAM‐dArUdAdA‐6‐TAMRA‐3′, (b) Kinetics data are plotted against substrate concentration, (c) The cleavage of the oligonucleotide is monitored on NuPAGE, and (d) DSF of the Nsp15 in the absence and presence of metal ions